Implantable Cardioverter-Defibrillator therapy for primary prevention of sudden cardiac death in patients with severe Chagas cardiomyopathy

Cardinalli-Neto, Augusto; Nakazone, Marcelo Arruda; Grassi, L; Tavares, Bruno Garcia; Bestetti, Reinaldo B.

doi:10.1016/j.ijcard.2011.03.036

Cited by 14 publications

(13 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the frequency of ventricular fibrillation was higher in Chagas than in non-Chagas disease patients. 60 Now, there is no reason to not advise ICD implantation for primary prevention of SCD in patients with CHF secondary to Chagas cardiomyopathy unless for economic constraints.…”

Section: Reviews | 23mentioning

confidence: 99%

The treatment of chronic heart failure secondary to Chagas cardiomyopathy in the contemporary era

Bestetti¹,

Daniel²

2016

ICFJ

View full text Add to dashboard Cite

<p>Chronic Heart Failure (CHF) affects about half patients with Chagas cardiomyopathy. Outcome of CHF secondary to Chagas cardiomyopathy is relentless with an annual mortality approaching 20%, which is higher than that observed in non-Chagas disease heart failure. The pathophysiology of Chagas disease is similar to that found in non-Chagas disease heart failure with a marked activation of the neurohormonal system. No randomized trial has been conducted in patients with Chagas cardiomyopathy with CHF to assess the effect of a drug on mortality of such patients. Therefore, the treatment of CHF secondary to Chagas cardiomyopathy relies on drugs prescribed to patients with non-Chagas disease heart failure<strong>. </strong>Patients with Chagas disease heart failure have been classified into stages A to D according to the American College of Cardiology/American Heart Association. Little can be done to patients in the stage A of CHF, except for treatment of comorbidities. In patients in the stage B of CHF, aldosterone receptor antagonist, angiotensin converting enzyme inhibitors (ACEI), and Betablockers (BB) can be indicated. In patients in the stage C of CHF, the same drugs are of value. In addition, diuretics, digoxin, angiotensin receptor blockers to patients intolerant to ACEI have also been used. Cardiac Resynchronization Therapy and Implantable Cardioverter Defibrillator may have indications similar to that of non-Chagas disease patients. In stage D of CHF, heart transplantation is a valid option for patients with this condition. </p>

show abstract

Section: Reviews | 23mentioning

confidence: 99%

The treatment of chronic heart failure secondary to Chagas cardiomyopathy in the contemporary era

Bestetti¹,

Daniel²

2016

ICFJ

View full text Add to dashboard Cite

show abstract

“…2 The main causes of death in chronic Chagas' cardiomyopathy (CChC) are progressive congestive heart failure and sudden cardiac death. [6][7][8] As economical resources for funding such as expensive therapy are limited in Latin America, it is of utmost importance to determine which patients are at a higher risk. Physicians around the world should become aware of its existence and how to recognize and treat it.…”

Section: Introductionmentioning

confidence: 99%

“…5 Implantable cardioverter defibrillators (ICDs) have been proven to be effective in reducing sudden death due to malignant ventricular arrhythmias in patients with CChC. [6][7][8] As economical resources for funding such as expensive therapy are limited in Latin America, it is of utmost importance to determine which patients are at a higher risk. Prior studies have identified older age and low ejection fraction as predictors of sudden death or appropriate therapies delivered by the ICD.…”

Section: Introductionmentioning

confidence: 99%

Fragmented Surface ECG Was a Poor Predictor of Appropriate Therapies in Patients with Chagas’ Cardiomyopathy and ICD Implantation (Fragmented ECG in CHAgas’ Cardiomyopathy Study)

Baranchuk

Femenía

López-Diez³

et al. 2013

Noninvasive Electrocardiol

View full text Add to dashboard Cite

show abstract

“…8 These conditions have a prevalence of 20 % in patients with severe Chagas heart failure (LVEF <35 %). 48 Cardinalli-Neto et al 48 observed that patients with Chagas heart failure have a higher incidence of repetitive ventricular tachycardia and/or ventricular fibrillation than those with non-Chagas heart failure. 48 These repetitive arrhythmias lead to shock occurrence in primary SCD prevention with an implantable cardioverter defibrillator (ICD).…”

Section: Medicalmentioning

confidence: 99%

Chagas Heart Failure in Patients from Latin America

Bestetti

2016

Cardiac Failure Review

View full text Add to dashboard Cite

Physicians working in Europe and the United States should suspect Chagas heart failure in every patient coming from Latin America with chronic heart failure. Diagnosis should be confirmed by positive serology. Right bundle branch block and left anterior fascicular block on 12-lead electrocardiogram, enlarged cardiac silhouette with no pulmonary congestion on chest X-ray and left ventricular apical aneurysm on echocardiography are the distinctive features of this condition. The clinical course is poorer than that of non-Chagas heart failure; however, medical treatment is similar. Implantable cardioverter-defibrillators are useful in the primary and secondary prevention of sudden cardiac death. Cardiac resynchronisation therapy can be given to patients on optimal medical therapy and with lengthened QRS complex. Heart transplantation is the treatment of choice for patients with end-stage Chagas heart failure.

show abstract

Implantable Cardioverter-Defibrillator therapy for primary prevention of sudden cardiac death in patients with severe Chagas cardiomyopathy

Cited by 14 publications

References 13 publications

The treatment of chronic heart failure secondary to Chagas cardiomyopathy in the contemporary era

The treatment of chronic heart failure secondary to Chagas cardiomyopathy in the contemporary era

Fragmented Surface ECG Was a Poor Predictor of Appropriate Therapies in Patients with Chagas’ Cardiomyopathy and ICD Implantation (Fragmented ECG in CHAgas’ Cardiomyopathy Study)

Chagas Heart Failure in Patients from Latin America

Contact Info

Product

Resources

About